André T et al; MOSAIC Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract

De Gramont A et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc ASCO 2007;Abstract 4007.

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Safety results of the international randomized MOSAIC trial. Proc ASCO 2002;Abstract 525.

Gelos M et al. Factors influencing lymph node harvest in colorectal surgery. Int J Colorectal Dis 2007;[Epub ahead of print]. Abstract

Gill S et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004;22(10):1797-806. Abstract

Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for State II and III colon cancer: Results from NSABP-C-07. J Clin Oncol 2007;25(16): 2198-204. Abstract

O’Connell MJ et al. Survival following recurrence in patients with adjuvant colon cancer: Findings from the 20,800-patient ACCENT dataset. Proc ASCO 2007;Abstract 4009.

Rajput A et al. Meeting the 12 lymph nodes(LN) benchmark in colorectal cancer surgery: A comparison of NCCN and SEER data. Proc ASCO 2007;Abstract 4015.

Sargent DJ et al. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800-patient (pt) ACCENT dataset. Proc ASCO 2007;Abstract 4008.

Susman E. Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncol 2006;7(4):288. No abstract available

Wolmark N et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc ASCO 2005;Abstract 3500.